Use of Terazosin to Treat Trauma-Related Nightmares After a Failed Trial of Prazosin

References (21)

1. Trauma- and Stressor-Related Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. DSM Library. American Psychiatric Association Publishing; 2022.
2. Kirkpatrick HA, Heller GM. Posttraumatic stress disorder: theory and treatment update. Int J Psychiatry Med. 2014;47(4):337–346. PubMed CrossRef
3. DeViva JC, Zayfert C, Pigeon WR, et al. Treatment of residual insomnia after CBT for PTSD: case studies. J Trauma Stress. 2005;18(2):155–159. PubMed CrossRef
4. Hendrickson RC, Raskind MA. Noradrenergic dysregulation in the pathophysiology of PTSD. Exp Neurol. 2016;284(Pt B):181–195. PubMed CrossRef
5. Miller LJ. Prazosin for the treatment of posttraumatic stress disorder sleep disturbances. Pharmacotherapy. 2008;28(5):656–666. PubMed CrossRef
6. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in posttraumatic stress disorder: a systematic review and meta-analysis. Sleep Med. 2020;67:225–231. PubMed CrossRef
7. Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003–1010. PubMed CrossRef
8. Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for posttraumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507–517. PubMed CrossRef
9. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–373. PubMed CrossRef
10. Koola MM, Varghese SP, Fawcett JA. High-dose prazosin for the treatment of posttraumatic stress disorder. Ther Adv Psychopharmacol. 2014;4(1):43–47. PubMed CrossRef
11. Terazosin: Drug information–UpToDate. Accessed May 11, 2023. https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information
12. Achari R, Laddu A. Terazosin: a new alpha adrenoceptor blocking drug. J Clin Pharmacol. 1992;32(6):520–523. PubMed CrossRef
13. Cai R, Zhang Y, Simmering JE, et al. Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases. J Clin Invest. 2019;129(10):4539–4549. PubMed CrossRef
14. Salviati M, Pallagrosi M, Valeriani G, et al. On the role of noradrenergic system in PTSD and related sleep disturbances. The use of terazosin in PTSD-related nightmares: a case report. Clin Ter. 2013;164(2):133–137. PubMed. 10.7417/CT.2013.1532
15. Nirmalani-Gandhy A, Sanchez D, Catalano G. Terazosin for the treatment of trauma-related nightmares: a report of 4 cases. Clin Neuropharmacol. 2015;38(3):109–111. PubMed CrossRef
16. Detweiler MB, Pagadala B, Candelario J, et al. Treatment of posttraumatic stress disorder nightmares at a Veterans Affairs medical center. J Clin Med. 2016;5(12):117. PubMed CrossRef
17. Terazosin Package Insert.pdf. Accessed July 22, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf
18. Minipress Package Insert. Accessed July 22, 2023. https://cdn.pfizer.com/pfizercom/products/uspi_minipress.pdf
19. Weathers FW, Bovin MJ, Lee DJ, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383–395. PubMed CrossRef
20. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379–1391. PubMed CrossRef
21. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No. 76-338. Rockville, MD: National Institute of Mental Health; 1976:217–222.